- Trials with a EudraCT protocol (23)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
23 result(s) found for: Epitopes.
Displaying page 1 of 2.
EudraCT Number: 2019-001731-31 | Sponsor Protocol Number: YFV_001 | Start Date*: 2019-09-02 | |||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||
Full Title: Cytotoxicity of Yellow Fever specific CD8 T cells Following YF-17D Vaccination | |||||||||||||
Medical condition: Healthy individuals or HIV-1 infected individuals | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001431-27 | Sponsor Protocol Number: CovidVal01 | Start Date*: 2020-06-05 |
Sponsor Name:Klinikum St. Georg gGmbH | ||
Full Title: Treatment of Sars-CoV2 infections (Covid-19) in patients without or with chronic kidney disease (CKD) with valsartan vs placebo, a three-armed randomized, partly blinded trial | ||
Medical condition: Sars-Cov2 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000365-33 | Sponsor Protocol Number: CHDR2043 | Start Date*: 2021-03-17 | |||||||||||
Sponsor Name:Molecular Partners AG | |||||||||||||
Full Title: A Phase 2a open label, non-comparative, single dose escalation study to evaluate the dynamics of viral clearance, pharmacokinetics and tolerability of ensovibep in patients with symptomatic COVID-1... | |||||||||||||
Medical condition: SARS-CoV-2 infection (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001070-38 | Sponsor Protocol Number: B-pVAC-SARS-CoV-2 | Start Date*: 2021-06-21 | |||||||||||
Sponsor Name:University Hospital Tuebingen | |||||||||||||
Full Title: B-pVAC-SARS-CoV-2: Phase I/II multi-center safety and immungenicity trial of multi-peptide vaccination to prevent COVID-19 infection in adults with B-cell/antibody deficiency | |||||||||||||
Medical condition: Adults with congenital or acquired B cell/antibody deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002571-16 | Sponsor Protocol Number: MBP8298-01 Amendment 04 | Start Date*: 2007-06-29 | |||||||||||
Sponsor Name:BioMS Technology Corp | |||||||||||||
Full Title: A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. | |||||||||||||
Medical condition: Secondary progressive multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) FI (Completed) DK (Completed) ES (Completed) EE (Completed) NL (Completed) LT (Prematurely Ended) LV (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000296-36 | Sponsor Protocol Number: ZWI-ZW25-301 | Start Date*: 2021-12-20 | ||||||||||||||||
Sponsor Name:Zymeworks BC Inc. | ||||||||||||||||||
Full Title: A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gast... | ||||||||||||||||||
Medical condition: Gastroesophageal Adenocarcinoma (GEA) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) PT (Ongoing) BE (Ongoing) ES (Ongoing) NL (Ongoing) IE (Ongoing) IT (Ongoing) EE (Ongoing) RO (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001250-21 | Sponsor Protocol Number: 2020/3078 | Start Date*: 2020-04-03 |
Sponsor Name:GUSTAVE ROUSSY | ||
Full Title: COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients | ||
Medical condition: Patients eligible for, or under, or recently treated by chemotherapy (CT) and/or immune-checkpoint blockade (ICB) for the treatment of solid tumors or hematological malignancies. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-000219-24 | Sponsor Protocol Number: 3082A-101342 | Start Date*: 2005-04-28 |
Sponsor Name:Wyeth Pharmaceuticals | ||
Full Title: A multicentre study to describe the immunogenic epitope(s) of factor VIII in previously treated patients with congenital haemophilia A who develop de novo factor VIII inhibitors while receiving fac... | ||
Medical condition: Haemophilia A is an X-linked recessive clotting disorder in which the clotting factor, factor VIII (FVIII), is deficient or inactive. Patients with low levels of FVIII have an increased tendency t... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) BE (Completed) ES (Completed) DE (Prematurely Ended) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-003188-90 | Sponsor Protocol Number: ENFORCE-PLUS | Start Date*: 2021-07-01 | |||||||||||
Sponsor Name:CHIP - Rigshospitalet - University of Copenhagen | |||||||||||||
Full Title: A Phase IV Vaccine Study under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE PLUS) | |||||||||||||
Medical condition: The primary objective of the study is to assess if the SARS-CoV-2 vaccine Johnson & Johnson/Janssen results in change in number and activation of platelets and anti-PF4 level. As well as to compare... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004669-15 | Sponsor Protocol Number: CP007A | Start Date*: 2014-06-16 | |||||||||||
Sponsor Name:Circassia Limited | |||||||||||||
Full Title: An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years after the Administration of Treatment | |||||||||||||
Medical condition: Treatment of cat allergen induced rhinoconjunctivitis in patients with clinically relevant symptoms | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000890-10 | Sponsor Protocol Number: MP0420-CP302 | Start Date*: 2021-05-03 | |||||||||||
Sponsor Name:Molecular Partners AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19 | |||||||||||||
Medical condition: Symptomatic COVID-19 in ambulatory patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018341-56 | Sponsor Protocol Number: VAC039 | Start Date*: 2010-05-07 |
Sponsor Name:University of Oxford | ||
Full Title: A phase I/IIa sporozoite challenge study to assess the safety, immunogenicity and protective efficacy of new malaria vaccine candidates; AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP... | ||
Medical condition: Malaria (plasmodium falciparum) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-000547-24 | Sponsor Protocol Number: CCRG11-001 | Start Date*: 2012-02-27 | ||||||||||||||||
Sponsor Name:Antwerp University Hospital | ||||||||||||||||||
Full Title: Therapeutic efficacy of Wilms' tumor gene (WT1) mRNA-electroporated autologous dendritic cell vaccination in patients with solid tumors: a phase I/feasibility study | ||||||||||||||||||
Medical condition: Therapeutic vaccination with dendritic cells loaded with Wilms' tumor 1 protein in patients with solid tumors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002687-41 | Sponsor Protocol Number: TA-8995-AD-1 | Start Date*: 2021-12-09 |
Sponsor Name:NewAmsterdam Pharma BV | ||
Full Title: A Phase 2a, Proof-of-Concept, Open-Label Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Obicetrapib in Patients with Early Alzheimer’s Disease (Hetero/Homozygote APOE4 Carr... | ||
Medical condition: Alzheimer's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-006003-42 | Sponsor Protocol Number: ENFORCE | Start Date*: 2020-12-30 | |||||||||||
Sponsor Name:CHIP - Rigshospitalet - University of Copenhagen | |||||||||||||
Full Title: National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE) | |||||||||||||
Medical condition: The aim is to study primarily effectiveness as well as safety of citizens being vaccinated with one of the SARS-CoV2 vaccines being applied in the Danish COVID-19 vaccine programme. Whereas ongoi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003164-27 | Sponsor Protocol Number: TW001-AD-C2.01 | Start Date*: 2022-06-28 | |||||||||||
Sponsor Name:Treeway TW001AD B.V. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of TW001 in Alzheimer Patients | |||||||||||||
Medical condition: Alzheimer´s Disease (AD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003666-13 | Sponsor Protocol Number: VAC89220HPX3002 | Start Date*: 2019-10-15 | |||||||||||
Sponsor Name:Janssen Vaccines & Prevention B.V. | |||||||||||||
Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1... | |||||||||||||
Medical condition: Prevention of HIV-1 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Restarted) PL (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015884-15 | Sponsor Protocol Number: IMPAACT-P1066 | Start Date*: 2011-06-30 | |||||||||||
Sponsor Name:The National Institute of Allergy and Infectious Diseases (NIAID) and The Eunice Kennedy Shriver NICHD | |||||||||||||
Full Title: A Phase I/II, Multicenter, Open-Label, Non comparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmac... | |||||||||||||
Medical condition: HIV | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003102-14 | Sponsor Protocol Number: IFG-NIB-01 | Start Date*: 2017-09-19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Institut für Frauengesundheit GmbH | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A PHASE II ONE-ARM OPEN-LABEL NEOADJUVANT STUDY OF PEMBROLIZUMAB IN COMBINATION WITH NAB-PACLITAXEL FOLLOWED BY PEMBROLIZUMAB IN COMBINATION WITH EPIRUBICIN AND CYCLOPHOSPHAMIDE IN PATIENTS WITH TR... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Female patients with early, neoadjuvantly treated, triple negative breast cancer. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-000827-94 | Sponsor Protocol Number: U-DANCE-anti-AML | Start Date*: 2016-09-08 | ||||||||||||||||
Sponsor Name:UMC Utrecht | ||||||||||||||||||
Full Title: A phase I/II post cord blood HCT dendritic cells vaccination trial directed against WT1 for pediatric acute myeloid leukemia: the U-DANCE-anti-AML trial | ||||||||||||||||||
Medical condition: AML: Acute Myeloid leukemia/ cancer of blood and bone marrow | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Not Authorised) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.